Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2016

01-07-2016 | Original Article

Promoter methylation and expression of CDH1 and susceptibility and prognosis of eyelid squamous cell carcinoma

Authors: Yong-Qiang Wang, Ye Yuan, Shan Jiang, Hua Jiang

Published in: Tumor Biology | Issue 7/2016

Login to get access

Abstract

Eyelid skin tumors are the most frequent type of cancer in ophthalmology. And, eyelid squamous cell carcinoma (SCC) accounts for a large part of it. CDH1 encodes E-cadherin, a glycoprotein that plays an important part in cell–cell interaction. Loss of CDH1 function was suspected to be associated with tumorigenesis. Methylation of CDH1 promotors can alter the expression of its protein and is also considered as a contributor to various cancers. In this study, CDH1 methylation and expression profile as well as prognosis of 38 cases of eyelid SCC and the corresponding adjacent tissues were analyzed to clarify the role of CDH1 methylation in SCC carcinogenesis and prognosis. Methylation was detected by PCR, and CDH1 expression was evaluated by immunohistochemistry. We observed that CDH1 methylation is significantly correlated with decreased CDH1 protein expression in eyelid SCC patients. Patients with methylation and low expression of CDH1 are significantly associated with advanced and aggressive phenotypes. Therefore, CDH1 methylation and CDH1 expression are both independent prognostic factors for prognosis of eyelid SCC patients.
Literature
1.
Deprez M, Uffer S. Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am J Dermatopathol. 2009;31:256–62.PubMed
2.
3.
Lin HY, Cheng CY, Hsu WM, Kao WH, Chou P. Incidence of eyelid cancers in taiwan: a 21-year review. Ophthalmology. 2006;113:2101–7.CrossRefPubMed
4.
Cook Jr BE, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology. 1999;106:746–50.CrossRefPubMed
5.
Hollestein LM, de Vries E, Nijsten T. Trends of cutaneous squamous cell carcinoma in the Netherlands: increased incidence rates, but stable relative survival and mortality 1989–2008. Eur J Cancer. 2012;48:2046–53.CrossRefPubMed
6.
Yin VT, Merritt HA, Sniegowski M, Esmaeli B. Eyelid and ocular surface carcinoma: diagnosis and management. Clin Dermatol. 2015;33:159–69.CrossRefPubMed
7.
Neale RE, Weissenborn S, Abeni D, Bavinck JNB, Euvrard S, Feltkamp MCW, et al. Human papillomavirus load in eyebrow hair follicles and risk of cutaneous squamous cell carcinoma. Cancer Epidemiol Biomark Prev. 2013;22:719–27.CrossRef
8.
Sullivan TJ, Boulton JE, Whitehead KJ. Intraepidermal carcinoma of the eyelid. Clin Exp Ophthalmol. 2002;30:23–7.CrossRefPubMed
9.
Faustina M, Diba R, Ahmadi MA, Esmaeli B. Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma. Ophthalmology. 2004;111:1930–2.CrossRefPubMed
10.
Asiaf A, Ahmad ST, Aziz SA, Malik AA, Rasool Z, Masood A, et al. Loss of expression and aberrant methylation of the cdh1 (e-cadherin) gene in breast cancer patients from Kashmir. Asian Pac J Cancer Prev : APJCP. 2014;15:6397–403.CrossRefPubMed
11.
Ibarrola-Villava M, Llorca-Cardenosa MJ, Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo JA, et al. Deregulation of arid1a, cdh1, cmet and pik3ca and target-related microrna expression in gastric cancer. Oncotarget. 2015;6:26935–45.CrossRefPubMedPubMedCentral
12.
Liang SC, Yang CY, Tseng JY, Wang HL, Tung CY, Liu HW, et al. Abcg2 localizes to the nucleus and modulates cdh1 expression in lung cancer cells. Neoplasia (New York, NY). 2015;17:265–78.CrossRef
13.
Martinelli M, Palmieri A, Rodia MT, Cura F, Scapoli L, Ugolini G, et al. Cdh1 polymorphisms and low expression of e-cadherin and beta-catenin in colorectal cancer patients. J Biol Regul Homeost Agents. 2015;29:89–96.PubMed
14.
Pei Y, Wang P, Liu H, He F, Ming L. Foxq1 promotes esophageal cancer proliferation and metastasis by negatively modulating cdh1. Biomed Pharmacother. 2015;74:89–94.CrossRefPubMed
15.
Zhao L, Wang YX, Xi M, Liu SL, Zhang P, Luo LL, et al. Association between e-cadherin (cdh1) polymorphisms and pancreatic cancer risk in Han Chinese population. Int J Clin Exp Pathol. 2015;8:5753–60.PubMedPubMedCentral
16.
Fatemi M, Pao MM, Jeong S, Gal-Yam EN, Egger G, Weisenberger DJ, et al. Footprinting of mammalian promoters: use of a cpg DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res. 2005;33, e176.CrossRefPubMedPubMedCentral
17.
Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27–56.PubMed
18.
Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta Int J Clin Chem. 2013;424:53–65.CrossRef
19.
Xue M, Lai SC, Wang LJ. Non-invasive DNA methylation biomarkers in colorectal cancer: a systematic review. J Dig Dis. 2015.
20.
Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, Harris NL, et al. The 2015 world health organization classification of tumors of the thymus: continuity and changes. J Thoracic Oncol : Off Publ Int Assoc Stud Lung Cancer. 2015;10:1383–95.CrossRef
21.
Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne AC, Lopez-Crapez E, et al. Brca1 promoter hypermethylation, 53bp1 protein expression and parp-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer. 2013;13:523.CrossRefPubMedPubMedCentral
22.
Shargh SA, Sakizli M, Khalaj V, Movafagh A, Yazdi H, Hagigatjou E, et al. Downregulation of e-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor. Med Oncol (Northwood, London, England). 2014;31:250.CrossRef
23.
Diniz-Freitas M, Garcia-Caballero T, Antunez-Lopez J, Gandara-Rey JM, Garcia-Garcia A. Reduced e-cadherin expression is an indicator of unfavourable prognosis in oral squamous cell carcinoma. Oral Oncol. 2006;42:190–200.CrossRefPubMed
24.
Zhai X, Zhu H, Wang W, Zhang S, Zhang Y, Mao G. Abnormal expression of emt-related proteins, s100a4, vimentin and e-cadherin, is correlated with clinicopathological features and prognosis in hcc. Med Oncol (Northwood, London, England). 2014;31:970.CrossRef
25.
Abascal MF, Besso MJ, Rosso M, Mencucci MV, Aparicio E, Szapiro G, et al. Cdh1/e-cadherin and solid tumors. An updated gene-disease association analysis using bioinformatics tools. Comput Biol Chem. 2015;60:9–20.CrossRefPubMed
26.
Li XW, Shi BY, Yang QL, Wu J, Wu HM, Wang YF, et al. Epigenetic regulation of cdh1 exon 8 alternative splicing in gastric cancer. BMC Cancer. 2015;15:954.CrossRefPubMedPubMedCentral
27.
Nelson WJ, Nusse R. Convergence of wnt, beta-catenin, and cadherin pathways. Science (New York, NY). 2004;303:1483–7.CrossRef
28.
Dou CY, Fan YC, Cao CJ, Yang Y, Wang K. Sera DNA methylation of cdh1, dnmt3b and esr1 promoters as biomarker for the early diagnosis of hepatitis b virus-related hepatocellular carcinoma. Dig Dis Sci. 2015.
29.
Lu H, Liu B, Zhang FJ, Zhang J, Dong R, Chen L, et al. The e3 ligase apc/c-cdh1 regulates mef2a-dependent transcription by targeting sumo-specific protease 2 for ubiquitination and degradation. Cell Cycle. 2014;13:3892–902.CrossRefPubMedPubMedCentral
30.
Wang D, Su L, Huang D, Zhang H, Shin DM, Chen ZG. Downregulation of e-cadherin enhances proliferation of head and neck cancer through transcriptional regulation of egfr. Mol Cancer. 2011;10:116.CrossRefPubMedPubMedCentral
Metadata
Title
Promoter methylation and expression of CDH1 and susceptibility and prognosis of eyelid squamous cell carcinoma
Authors
Yong-Qiang Wang
Ye Yuan
Shan Jiang
Hua Jiang
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4851-2

Other articles of this Issue 7/2016

Tumor Biology 7/2016 Go to the issue

Original Article

Evaluation of 188Re-labeled NGR–VEGI protein for radioimaging and radiotherapy in mice bearing human fibrosarcoma HT-1080 xenografts

Original Article

Down-regulation of miR-320 associated with cancer progression and cell apoptosis via targeting Mcl-1 in cervical cancer

Original Article

Expression and mechanisms of long non-coding RNA genes MEG3 and ANRIL in gallbladder cancer

Original Article

Decreased CK1δ expression predicts prolonged survival in colorectal cancer patients

Original Article

Silencing A7-nAChR levels increases the sensitivity of gastric cancer cells to ixabepilone treatment

Original Article

Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits